Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
8264 | 1201 | 21.9 | 83% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
126 | 23061 | TRANSPLANTATION//TRANSPLANTATION PROCEEDINGS//MYCOPHENOLIC ACID |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | NEORAL | Author keyword | 35 | 67% | 3% | 32 |
2 | C2 MONITORING | Author keyword | 26 | 87% | 1% | 13 |
3 | C 2 MONITORING | Author keyword | 19 | 70% | 1% | 16 |
4 | SANDIMMUNE | Author keyword | 8 | 100% | 0% | 5 |
5 | PREPRANDIAL ADMINISTRATION | Author keyword | 6 | 80% | 0% | 4 |
6 | ABSORPTION PROFILING | Author keyword | 3 | 100% | 0% | 3 |
7 | C 2 LEVELS | Author keyword | 3 | 100% | 0% | 3 |
8 | NFAT REGULATED GENE EXPRESSION | Author keyword | 3 | 100% | 0% | 3 |
9 | PHARMACODYNAMIC MONITORING | Author keyword | 3 | 35% | 1% | 7 |
10 | CYCLOSPORINE MICROEMULSION | Author keyword | 3 | 50% | 0% | 4 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | NEORAL | 35 | 67% | 3% | 32 | Search NEORAL | Search NEORAL |
2 | C2 MONITORING | 26 | 87% | 1% | 13 | Search C2+MONITORING | Search C2+MONITORING |
3 | C 2 MONITORING | 19 | 70% | 1% | 16 | Search C+2+MONITORING | Search C+2+MONITORING |
4 | SANDIMMUNE | 8 | 100% | 0% | 5 | Search SANDIMMUNE | Search SANDIMMUNE |
5 | PREPRANDIAL ADMINISTRATION | 6 | 80% | 0% | 4 | Search PREPRANDIAL+ADMINISTRATION | Search PREPRANDIAL+ADMINISTRATION |
6 | ABSORPTION PROFILING | 3 | 100% | 0% | 3 | Search ABSORPTION+PROFILING | Search ABSORPTION+PROFILING |
7 | C 2 LEVELS | 3 | 100% | 0% | 3 | Search C+2+LEVELS | Search C+2+LEVELS |
8 | NFAT REGULATED GENE EXPRESSION | 3 | 100% | 0% | 3 | Search NFAT+REGULATED+GENE+EXPRESSION | Search NFAT+REGULATED+GENE+EXPRESSION |
9 | PHARMACODYNAMIC MONITORING | 3 | 35% | 1% | 7 | Search PHARMACODYNAMIC+MONITORING | Search PHARMACODYNAMIC+MONITORING |
10 | CYCLOSPORINE MICROEMULSION | 3 | 50% | 0% | 4 | Search CYCLOSPORINE+MICROEMULSION | Search CYCLOSPORINE+MICROEMULSION |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MICROEMULSION FORMULATION | 170 | 64% | 14% | 169 |
2 | SANDIMMUNE | 66 | 70% | 5% | 55 |
3 | TROUGH LEVELS | 37 | 46% | 5% | 60 |
4 | SANDIMMUN | 31 | 82% | 1% | 18 |
5 | CYCLOSPORINE PHARMACOKINETICS | 29 | 44% | 4% | 50 |
6 | ORAL FORMULATION | 28 | 57% | 3% | 33 |
7 | POST DOSE LEVELS | 21 | 78% | 1% | 14 |
8 | ABBREVIATED KINETIC PROFILES | 15 | 82% | 1% | 9 |
9 | IMMEDIATE POSTTRANSPLANT PERIOD | 14 | 100% | 1% | 7 |
10 | CONSUPREN | 12 | 86% | 0% | 6 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The clinical benefits of cyclosporine C2-level monitoring: A systematic review | 2007 | 48 | 49 | 94% |
Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis | 2015 | 1 | 55 | 71% |
Use of neoral C-2 monitoring: a European consensus | 2005 | 45 | 33 | 82% |
Therapeutic monitoring of calcineurin inhibitors for the nephrologist | 2007 | 73 | 102 | 43% |
Generic Immunosuppression in Solid Organ Transplantation: A Canadian Perspective | 2012 | 18 | 62 | 58% |
Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients | 2000 | 80 | 19 | 89% |
Clinical validation studies of Neoral C-2 monitoring: A review | 2002 | 91 | 22 | 91% |
Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: Review of current algorithms | 2001 | 74 | 80 | 65% |
Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs | 2013 | 8 | 20 | 55% |
Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I | 2009 | 16 | 108 | 61% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RENAL MED C | 2 | 23% | 0.7% | 9 |
2 | IMMUNOL HAEMATOL ONCOL BONE MARROW TRANSPLA | 2 | 67% | 0.2% | 2 |
3 | TRANSPLANT IMMUNOL INNOVAT ANTIREJECT THER | 1 | 38% | 0.2% | 3 |
4 | CLIN POLYCLIN UROL | 1 | 50% | 0.2% | 2 |
5 | CLIN S210622 | 1 | 100% | 0.2% | 2 |
6 | HLTH TRANSPLANTAT | 1 | 100% | 0.2% | 2 |
7 | INVEST NEFROL METAB MINERAL | 1 | 50% | 0.2% | 2 |
8 | PAEDIAT IMMUNOHAEMATOL BONE MARROW TRANSPL | 1 | 50% | 0.2% | 2 |
9 | CLIN PHARMACOL S210739 | 1 | 50% | 0.1% | 1 |
10 | DIPARTIMENTO NEFROL UROL TR IANTO RENALE | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000277568 | CYCLOSPORINE G//CYCLOSPORINE METABOLITES//CYCLOSPORIN G |
2 | 0.0000175133 | CYP3A5//TACROLIMUS//CYTOCHROME P450 3A5 |
3 | 0.0000107846 | MYCOPHENOLIC ACID//MYCOPHENOLIC ACID GLUCURONIDE//MYCOPHENOLATE MOFETIL |
4 | 0.0000081964 | IMMUKNOW//IMMUNE FUNCTION ASSAY//CYLEX IMMUKNOW ASSAY |
5 | 0.0000080681 | SIROLIMUS//EVEROLIMUS//PROLIFERATION SIGNAL INHIBITORS |
6 | 0.0000077411 | ACRODERMATITIS CONTINUA OF HALLOPEAU//VOCLOSPORIN//MICROEMULSION FORMULATION |
7 | 0.0000075992 | FK 506//FUJISAWA AMER//FUJISAWA AMER INC |
8 | 0.0000062378 | STEROID WITHDRAWAL//CORTICOSTEROID WITHDRAWAL//EARLY STEROID WITHDRAWAL |
9 | 0.0000053913 | SUBCLINICAL REJECTION//PROTOCOL BIOPSY//ALBERTA TRANSPLANT PL GENOM |
10 | 0.0000053795 | SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION//DUAL ORGAN TRANSPLANTATION//COMBINED TRANSPLANTATION |